Furthermore, we show that DZNep treatment alone or in context of SARS‐CoV or SARS‐CoV‐2 infections reduces abundance of pulmonary fibrosis markers (e.g., SERPINE1, MMP14, and COL4A1) and increases levels of factors with antifibrotic activity (e.g., HOPX, PI3/ELAFIN, and SLPI; Fig 4D). This evidence concerns the gene SLPI and pulmonary fibrosis.